Picture of Xvivo Perfusion AB logo

XVIVO Xvivo Perfusion AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Annual cashflow statement for Xvivo Perfusion AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line5.29-57.36.6722.394.5
Depreciation
Non-Cash Items3.7349.47.2-14.7-78.3
Unusual Items
Other Non-Cash Items
Changes in Working Capital-4.38-4.36-25.9-22-46.2
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Other Operating Cash Flow
Cash from Operating Activities29.5-12.3-12.127.946.3
Capital Expenditures-83.7-64.7-94.1-131-144
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-0.151-202-93.6-66.7-17.7
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-83.8-267-188-198-162
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities25.6483235-6.84419
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-27.119444.5-152300